eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

2/2021
vol. 13
 
Share:
Share:
more
 
 
abstract:
Original paper

Clinical outcomes following high-dose-rate surface applicator brachytherapy for angiosarcoma of scalp and face

Devarati Mitra
1
,
Phillip M. Devlin
2
,
Ivan Buzurovic
1
,
Katherine Thornton
3
,
Allen C. Lam
4
,
Chandrajit P. Raut
5, 6
,
Elizabeth H. Baldini
1, 5
,
Miranda B. Lam
1, 5

1.
Department of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
2.
Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
3.
Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
4.
Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
5.
Sarcoma and Bone Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA
6.
Department of Surgery, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
J Contemp Brachytherapy 2021; 13, 2: 172–178
Online publish date: 2021/04/14
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Angiosarcoma is a sub-type of soft tissue sarcoma, often presenting as a multifocal or diffuse disease process with poor prognosis. This study presents outcomes of a single institution cohort of patients with angiosarcoma of the scalp and face following treatment with multimodality therapy, including high-dose-rate surface applicator (HDR-SA) brachytherapy, and represents the largest cohort utilizing this therapeutic approach.

Material and methods
Twenty patients with primary or recurrent angiosarcoma of the face or scalp were treated with HDR-SA brachytherapy between 2003-2018, with clinical characteristics and outcomes collected from medical records and used to identify prognostic features.

Results
Median follow-up was 45 months. Patients treated with HDR-SA brachytherapy had a 4-year local control rate of 63%, a 4-year progression-free survival (PFS) rate of 20%, and a 4-year overall survival rate of 54%. Disease features associated with worse loco-regional control (LRC) included location on the scalp (vs. face, p = 0.04) and tumor size ≥ 5 cm (p = 0.0099). Outcomes after HDR-SA brachytherapy for salvage therapy vs. HDR-SA brachytherapy as a component of an initial treatment approach were also significantly different, with worse LRC (p = 0.0084) and worse overall survival (OS) (p = 0.0019) in a setting of salvage therapy.

Conclusions
Local control rates following HDR-SA brachytherapy for scalp or face angiosarcoma are moderate and similar to what is described in the literature using a variety of local control treatment modalities. Smaller tumors and those involving the face rather than scalp had better outcomes. PFS rates were poor and there is a pressing need for treatment intensification and novel therapeutic options.

keywords:

HDR brachytherapy, angiosarcoma

 
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe